Covid-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: In addition to the routine treatment regimen, patients will receive a puff of PHR spray 160 (6 micrograms per puff) using a spacer,10 times a day during10 days. PH
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Male or female patients aged 18 to 75 years with COVID-19 who have been diagnosed with a lung scan, PCR, or clinical examination. Obtaining informed consent from the patient or patient caregiver to participate in the study
Exclusion criteria
Exclusion criteria: Cancer patients undergoing chemotherapy Patients with immunodeficiency diseases receiving immunomodulators Patients with uncontrolled heart, kidney or liver failure Women who are pregnant or breastfeeding Patients with low level of consciousness who are not able to inhale the spray
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of arterial oxygen saturation. Timepoint: Before and after intervention on a daily basis. Method of measurement: Pulse oximeter.;Severity of cough. Timepoint: Before and after intervention on a daily basis. Method of measurement: Based on the degree of severity.;Shortness of breath. Timepoint: Before and after intervention on a daily basis. Method of measurement: Based on the degree of severity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay in hospital. Timepoint: By day. Method of measurement: Number of days.;ICU admision time. Timepoint: By day. Method of measurement: Number of days. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Razzaqi
Kashan University of Medical Sciences
Outcome results
None listed